<SEC-DOCUMENT>0001193125-25-266842.txt : 20251105
<SEC-HEADER>0001193125-25-266842.hdr.sgml : 20251105
<ACCEPTANCE-DATETIME>20251105160037
ACCESSION NUMBER:		0001193125-25-266842
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20251105
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251105
DATE AS OF CHANGE:		20251105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYTOKINETICS INC
		CENTRAL INDEX KEY:			0001061983
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				943291317
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50633
		FILM NUMBER:		251453702

	BUSINESS ADDRESS:	
		STREET 1:		350 OYSTER POINT BOULEVARD
		STREET 2:		.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 624-3000

	MAIL ADDRESS:	
		STREET 1:		350 OYSTER POINT BOULEVARD
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cytk-20251105.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-11-05T15:53:51.5536+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:cytk="http://cytokinetics.com/20251105" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_70228bea-6f57-4a6c-acc1-ada482a04bae" name="dei:AmendmentFlag" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7">false</ix:nonNumeric><ix:nonNumeric id="F_f28bb2b3-0af5-4451-838f-269fcb5935fa" name="dei:EntityCentralIndexKey" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7">0001061983</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cytk-20251105.xsd"/></ix:references><ix:resources><xbrli:context id="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001061983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-05</xbrli:startDate><xbrli:endDate>2025-11-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_512083fb-19fc-4335-8dff-d3e6fb2f3ba1" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_15d5141c-9406-45b1-8f86-dcd282e12827" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">November 05, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1336f4d-3200-4307-831f-8faa3f0926cd" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cytokinetics, Incorporated</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_be221fad-c564-4e96-ad93-ad32a2cc1da5" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_70d8bc4a-c476-4ae0-93cb-83c921b735d4" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">000-50633</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_96b9266c-7ef5-4993-a0b9-985cf4760737" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94-3291317</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7ded9270-6dd4-49f5-9b5c-352d077a7fa7" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">350 Oyster Point Boulevard</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_aa31b3cb-622c-4d0f-8047-c63a39766d8f" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_746461e0-9411-438f-a3c7-c40463f6602a" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_508c1ef9-8fee-4dbd-8ee9-72b10d9ba603" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94080</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_afaf7e71-27c6-48b3-a507-e67296b62ecc" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_1b7a7d51-7c6e-4e71-a9ae-e948813e7fb1" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">624-3000</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">n/a</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d19c1c6a-98d9-4c29-9959-7c5e71761d91" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f20638e8-746b-4942-97ca-c95f03095864" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ccd98a4d-3b69-48f3-afd2-04684debb5a5" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0967a0b4-0f43-4a03-9e0d-37da1e486e9b" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_19030593-36cb-4dfc-adcf-533fcda9e460" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0cc71bd1-8a2f-4cf3-81fc-83ca73446609" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CYTK</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ff1cc826-8970-4197-a9fd-6b8705b96e80" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_be6194d2-0ecc-4532-8f65-612b8cf82293" contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 5, 2025, Cytokinetics, Incorporated announced its financial results for the third quarter ended September 30, 2025.  The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02 and under Exhibit 99.1 shall not be considered &#8220;filed&#8221; under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered &#8220;filed&#8221; or incorporated by reference therein.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99.1 </span><a href="cytk-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Press Release dated November 5, 2025</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104 The cover page of this report has been formatted in Inline XBRL</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CYTOKINETICS, INCORPORATED</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John O. Faurescu</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John O. Faurescu<br/>SVP, Deputy General Counsel &amp; Secretary</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cytk-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-11-05T15:53:51.6953+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img114956760_0.jpg" alt="img114956760_0.jpg" style="width:182px;height:79px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CYTOKINETICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND PROVIDES BUSINESS UPDATE</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ex-U.S. Regulatory Reviews of Aficamten Ongoing in China and E.U.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">~$1.25 Billion in Cash, Cash Equivalents and Investments as of September 30, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOUTH SAN FRANCISCO, Calif., Nov. 5, 2025 - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;I&#x2019;m pleased that our teams continue to demonstrate strong execution and sustained momentum as we approach the PDUFA date for the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> NDA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our commercial preparations have been deliberate and strategic, positioning us well for this milestone,&#x201d; said Robert I. Blum, Cytokinetics&#x2019; President and Chief Executive Officer. &#x201c;During the third quarter, we expanded the evidence base for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with MAPLE-HCM further reinforcing the potential of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in patients with obstructive HCM. With a strong balance sheet, clear focus, and a deep commitment to our mission, we are entering this pivotal transformation toward potential commercialization with confidence, alignment and purpose as we aim to deliver on the promise of translating our science to a new medicine for patients.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Q3 and Recent Highlights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cardiac Muscle Programs</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (cardiac myosin inhibitor)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued to support the review of the New Drug Application (NDA) for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM) by the U.S. Food and Drug Administration (FDA) ahead of the Prescription Drug User Fee Act (PDUFA) action date of December 26, 2025. </font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 15, 2025, the Company participated in a Late Cycle Meeting with the FDA regarding the NDA for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in which the Company discussed its proposed Risk Evaluation and Mitigation Strategy (REMS) program, including Elements to Assure Safe Use (ETASU) and anticipated post-marketing requirements. Based on the Company&#x2019;s discussions and communications with FDA to date, the Company continues to expect a differentiated label and risk mitigation profile for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if approved by the FDA. </font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Submitted responses to the Day 120 List of Questions from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) with respect to the ongoing review of the Marketing Authorization Application (MAA) for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the treatment of obstructive HCM in the European Union and received the Day 180 List of Questions. We expect a potential EMA decision regarding the MAA in 1H 2026. </font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued to support the review of the NDA for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for obstructive HCM by the Center for Drug Evaluation (CDE) in China. </font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Presented primary results from MAPLE-HCM (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">M</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">etoprolol</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vs </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">P</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">atients with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">L</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VOT Obstruction on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">xercise Capacity in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HCM</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), a Phase 3 randomized, double-blind, active-comparator clinical trial, at the European Society of Cardiology Congress 2025 demonstrating superiority of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">metoprolol </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on peak oxygen uptake (pVO</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) (change from baseline to Week 24, least squares mean (LSM) treatment difference (SE), +2.3 (0.39) mL/kg/min, p&lt;0.001). </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">also showed superiority to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">metoprolol </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in five of six secondary endpoints, including improvement of New York Heart Association (NYHA) Functional Class and reduced patient symptom burden. Additional analyses showed </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significantly improved measures of cardiac structure and function compared to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">metoprolol</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental analyses of MAPLE-HCM presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 showed that </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significantly improved measures of maximal and submaximal exercise capacity and recovery compared to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">metoprolol. </font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Presented new analyses from the European Society of Cardiology Congress 2025 and the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 expanding on the long-term safety, efficacy and tolerability of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in patients with obstructive HCM and non-obstructive HCM. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advanced the ongoing clinical trials program for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten: </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued conduct of ACACIA-HCM (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ssessment </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">omparing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to Placebo on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ardiac Endpoints </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dults with Non-Obstructive </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HCM</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), a pivotal Phase 3 clinical trial of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in patients with non-obstructive HCM. Completed enrollment in the Japan cohort of ACACIA-HCM. We expect to share topline results of the primary cohort (excluding Japan) in Q2 2026. </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued conduct of CAMELLIA-HCM, a Phase 3 clinical trial of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in Japanese patients with obstructive HCM. CAMELLIA-HCM is being conducted by Bayer in collaboration with Cytokinetics to support potential marketing authorization in Japan.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued enrolling patients in CEDAR-HCM (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">linical </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">valuation of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">osing with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">educe Obstruction in a Pediatric Population in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HCM</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), a clinical trial of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a pediatric population with symptomatic obstructive HCM. We expect to continue patient enrollment of the adolescent cohort into 2026.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expanded U.S. commercial readiness activities for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten:</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued sales force onboarding and training.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finalized our promotional launch campaign and continued building our patient support programs. </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onboarded and began training patient navigators as a central point of contact throughout the treatment experience. </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued to engage with payers to educate on the clinical data supportive of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the clinical and economic burden of HCM. </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advanced European commercial readiness activities, including preparing Health Technology Assessment (HTA) dossiers for key EU markets and ensuring launch readiness for potential approval in Germany in 1H 2026. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Published the following manuscripts: </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Metoprolol</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Monotherapy for Obstructive Hypertrophic Cardiomyopathy&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New England Journal of Medicine</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Effect of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Compared With </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Metoprolol</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Journal of the American College of Cardiology</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Low Incidence of Atrial Fibrillation in Patients with Obstructive Hypertrophic Cardiomyopathy treated with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM Trials&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Heart Rhythm</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Circulation</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Safety and Efficacy of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Journal of Cardiac Failure</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta-Analysis&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Journal of the American Heart Association</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Toward a Quantitative Understanding of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Clinical Pharmacology: Population Pharmacokinetic Modeling&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CPT: Pharmacometrics &amp; Systems Pharmacology</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Cardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Journal of the American Heart Association</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Health Care Resource Use and Economic Burden in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Journal of the American Heart Association</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.648%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">omecamtiv mecarbil</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (cardiac myosin activator)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued conduct of COMET-HF (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">onfirmation of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">O</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">mecamtiv </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">M</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ecarbil</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fficacy </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rial in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">H</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eart</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> F</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ailure), a confirmatory Phase 3 clinical trial of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">omecamtiv mecarbil</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in patients with symptomatic heart failure with severely reduced ejection fraction. We expect to continue patient enrollment through 2026.</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ulacamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (CK-4021586, cardiac myosin inhibitor)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued conduct of AMBER-HFpEF (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ssessment of CK-586 in a </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">M</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ulti-Center, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">linded </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">valuation of Safety and Tolerability </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">esults in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HFpEF</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), a Phase 2 clinical trial of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ulacamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) &#x2265; 60%. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clinical Development and Ongoing Research</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued pre-clinical development and research activities directed to additional muscle biology focused programs.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Named James M. Daly to the Company&#x2019;s Board of Directors. Mr. Daly is an accomplished pharmaceutical industry leader with expertise in commercialization.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Quarter 2025 Financial Results</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Equivalents and Investments</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of September 30, 2025, the company had approximately $1.25 billion in cash, cash equivalents and investments compared to $1.04 billion at June 30, 2025.</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 19, 2025, the Company issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the &#x201c;Notes&#x201d;), which includes the full exercise of the initial purchasers&#x2019; option to purchase up to an additional $100.0 million aggregate principal amount of Notes. Net proceeds from the offering were $729.5 million after deducting the initial purchasers&#x2019; discount and commissions and offering expenses payable by the Company. The Company used approximately $402.5 million of the net proceeds from the offering and issued 2,168,806 shares of its common stock in exchange for approximately $399.5 million aggregate principal amount of the 2027 Notes in privately negotiated transactions entered into concurrently with the pricing of the offering.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, the Company received $100 million in proceeds from the drawing on Tranche 5 of the Royalty Pharma Multi Tranche Term Loan.</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total revenues for the third quarter of 2025 were $1.9 million compared to $0.5 million for the same period in 2024.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development (R&amp;D) Expenses</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D expenses for the third quarter of 2025 were $99.2 million, which included $15.1 million of non-cash stock-based compensation expense, compared to $84.6 million for the same period in 2024, which included $11.4 million of non-cash stock-based compensation expense. The increase was primarily due to advancing our clinical trials and higher personnel-related costs including stock-based compensation.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and Administrative (G&amp;A) Expenses</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">G&amp;A expenses for the third quarter of 2025 were $69.5 million, which included $15.6 million of non-cash stock-based compensation expense, compared to $56.7 million for the same period in 2024, which included $13.9 million of non-cash stock-based compensation expense. The increase was primarily due to investments toward commercial readiness and higher personnel-related costs including stock-based compensation.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Income (Loss)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net loss for the third quarter of 2025 was $306.2 million, or $(2.55) per share, basic and diluted, compared to a net loss of $160.5 million, or $(1.36) per share, basic and diluted, for the same period in 2024. The net loss for the third quarter of 2025 includes the debt conversion expense of $121.2 million due to the induced exchange of $399.5 million of aggregate principal amount of the 2027 Notes.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025 Financial Guidance</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company is updating its full year 2025 financial guidance:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:44.12%;box-sizing:content-box;"></td>
     <td style="width:27.94%;box-sizing:content-box;"></td>
     <td style="width:27.94%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-top:0.5pt solid #bfbfbf;padding-top:0in;border-right:0.5pt solid #bfbfbf;border-left:0.5pt solid #bfbfbf;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #bfbfbf;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid #bfbfbf;padding-top:0in;border-right:0.5pt solid #bfbfbf;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #bfbfbf;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current Guidance</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">issued on 11/5/2025</font></p></td>
     <td style="border-top:0.5pt solid #bfbfbf;padding-top:0in;border-right:0.5pt solid #bfbfbf;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #bfbfbf;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Prior Guidance</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #bfbfbf;border-left:0.5pt solid #bfbfbf;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #bfbfbf;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">GAAP operating expense*</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #bfbfbf;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #bfbfbf;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$680 million to $700 million</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #bfbfbf;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #bfbfbf;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$670 million to $710 million</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #bfbfbf;border-left:0.5pt solid #bfbfbf;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #bfbfbf;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-cash stock-based compensation expense included in GAAP operating expense</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #bfbfbf;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #bfbfbf;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$120 million to $110 million</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #bfbfbf;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #bfbfbf;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$120 million to $110 million</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*GAAP operating expense comprised of R&amp;D and SG&amp;A expenses.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anticipated year-over-year increase in GAAP operating expense includes investments toward commercial readiness for the potential approval and launch of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for patients with obstructive HCM.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial guidance does not include the effect of GAAP adjustments as may be caused by events that occur subsequent to publication of this guidance, including but not limited to Business Development activities.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conference Call and Webcast Information</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Members of Cytokinetics&#x2019; senior management team will review the company&#x2019;s third quarter 2025 results on a conference call today at 4:30 PM Eastern Time. The conference call will be simultaneously webcast and can be accessed from the Investors &amp; Media section of Cytokinetics&#x2019; website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.cytokinetics.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or directly at the following link: </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cytokinetics Q3 2025 Earnings Conference Call</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An archived replay of the webcast will be available via Cytokinetics&#x2019; website for six months.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About Cytokinetics</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">omecamtiv mecarbil</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ulacamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a cardiac myosin inhibitor with a mechanism of action distinct from </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information about Cytokinetics, visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.cytokinetics.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and follow us on </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">X</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facebook</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">YouTube</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclaimer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten, omecamtiv mecarbil, ulacamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the &#x201c;Act&#x201d;). Cytokinetics claims the protection of the Act&#x2019;s Safe Harbor for forward-looking statements. Examples of such statements include, but not limited to, statements, express or implied, relating to our or our partners&#x2019; research and development and commercial readiness activities, including the initiation, conduct, design, enrollment, progress, continuation, completion, timing and results of any of our clinical trials, or more specifically, our receipt of regulatory approval by FDA or any other regulatory authority to enable our commercialization of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the United States by the target PDUFA date or in any other jurisdiction by any target date, if ever, our ability to complete enrollment of CEDAR-HCM and AMBER-HFpEF by any target date, our ability to complete patient enrollment of COMET-HF by any target date, our ability to announce the results of ACACIA-HCM in of the second quarter of 2026, our ability to announce the results of any of our clinical trials by any particular date, the timing of interactions with FDA or any other regulatory authorities in connection to any of our drug candidates and the outcomes of such interactions; statements relating to the potential patient population who could benefit from </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">omecamtiv mecarbil</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ulacamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, CK-089 or any of our other drug candidates; statements relating to our ability to receive additional capital or other funding, including, but not limited to, our ability to meet any of the conditions relating to or to otherwise secure additional loan disbursements under any of our agreements with entities affiliated with Royalty Pharma or additional milestone payments from Sanofi or Bayer in connection with our collaborations for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in China or Japan respectively; statements relating to our operating expenses or cash utilization for the remainder of 2025 or any other period, and statements relating to our cash balance at any particular date or the amount of cash runway such cash balances represent at any particular time. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to Cytokinetics&#x2019; need for additional funding and such additional funding may not be available on acceptable terms, if at all; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics&#x2019; drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; the FDA or foreign regulatory agencies may delay or limit Cytokinetics&#x2019; or its partners&#x2019; ability to conduct clinical trials; Cytokinetics may incur unanticipated research and development and other costs; standards of care may change, rendering Cytokinetics&#x2019; drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics&#x2019; drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics&#x2019; business, investors should consult Cytokinetics&#x2019; filings with the Securities and Exchange Commission, particularly under the caption &#x201c;Risk Factors&#x201d; in Cytokinetics&#x2019; Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Forward-looking statements are not guarantees of future performance, and Cytokinetics&#x2019; actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CYTOKINETICS&#174; and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">###</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cytokinetics</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diane Weiser</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Vice President, Corporate Affairs</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(415) 290-7757</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:57.928%;box-sizing:content-box;"></td>
     <td style="width:2.08%;box-sizing:content-box;"></td>
     <td style="width:18.936%;box-sizing:content-box;"></td>
     <td style="width:2.08%;box-sizing:content-box;"></td>
     <td style="width:18.976%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cytokinetics, Incorporated</font></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</font></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30, 2025</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</font></p></td>
    </tr>
    <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(unaudited)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;ASSETS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Current assets:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Cash and short term investments</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                    962,535</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                 1,076,014</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Other current assets</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;14,814</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;31,926</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total current assets</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;977,349</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,107,940</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Long-term investments</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;288,817</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;145,055</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Property and equipment, net</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;76,001</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;65,815</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating lease right-of-use assets</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;77,580</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;75,158</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Other assets</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;16,810</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,705</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total assets</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                 1,436,557</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                 1,401,673</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;LIABILITIES AND STOCKHOLDERS&#x2019; DEFICIT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Current liabilities:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Accounts payable and accrued liabilities</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                      83,717</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                      75,692</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Short-term operating lease liabilities</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,647</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;18,978</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Current portion of long-term debt</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;17,280</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;11,520</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Derivative liabilities measured at fair value</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;16,900</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;11,300</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Deferred revenue</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,612</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;52,370</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Other current liabilities</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,988</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9,814</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total current liabilities</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;142,144</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;179,674</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Term loan, net</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;158,747</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;93,227</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Convertible notes, net</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;889,524</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;552,370</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Liabilities related to revenue participation right purchase agreements, net</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;504,498</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;462,192</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Long-term operating lease liabilities</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;110,655</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;112,582</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Liabilities related to RPI Transactions measured at fair value</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;150,500</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;137,000</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Other non-current liabilities</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;1,612</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total liabilities</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,957,680</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,537,045</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Commitments and contingencies</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Stockholders' deficit</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:57.928%;box-sizing:content-box;"></td>
     <td style="width:2.08%;box-sizing:content-box;"></td>
     <td style="width:18.936%;box-sizing:content-box;"></td>
     <td style="width:2.08%;box-sizing:content-box;"></td>
     <td style="width:18.976%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Common stock</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;122</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;118</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Additional paid-in capital</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,782,409</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,563,876</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Accumulated other comprehensive income</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;34</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,398</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Accumulated deficit</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3,303,688)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2,701,764)</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total stockholders' deficit</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(521,123)</font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(135,372)</font></p></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total liabilities and stockholders' deficit</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:7.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                 1,436,557</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                 1,401,673</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="range_a6_i25">&#160;</p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:43.089%;box-sizing:content-box;"></td>
     <td style="width:1.96%;box-sizing:content-box;"></td>
     <td style="width:12.402%;box-sizing:content-box;"></td>
     <td style="width:2.801%;box-sizing:content-box;"></td>
     <td style="width:12.362%;box-sizing:content-box;"></td>
     <td style="width:1.96%;box-sizing:content-box;"></td>
     <td style="width:11.662%;box-sizing:content-box;"></td>
     <td style="width:2.1%;box-sizing:content-box;"></td>
     <td style="width:11.662%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cytokinetics, Incorporated</font></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations</font></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands except per share data)</font></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(unaudited)</font></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nine Months Ended</font></p></td>
    </tr>
    <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30, 2025</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30, 2024</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30, 2025</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30, 2024</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenues</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$          1,936</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             463</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$          5,931</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$          1,547</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and milestone revenues</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;64,353</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.333%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.333%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,936</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;463</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;70,284</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,547</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;99,233</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;84,612</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;311,628</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;245,779</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;69,458</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;56,652</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;192,548</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;152,976</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.333%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:3.333%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;168,691</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;141,264</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;504,176</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;398,755</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating loss</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(166,755)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(140,801)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(433,892)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(397,208)</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(11,353)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(8,928)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(31,305)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(28,763)</font></p></td>
    </tr>
    <tr style="height:25.9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash interest expense on liabilities related to revenue participation right purchase agreements</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(14,969)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(13,370)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(42,228)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(35,155)</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;10,248</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;17,054</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;36,950</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;36,520</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;700</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;700</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3,300</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;100</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of liabilities related to RPI Transactions</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(2,800)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(15,200)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(13,500)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(15,000)</font></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt conversion expense</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:1.667%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(121,249)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(121,249)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$     (306,178)</font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$     (160,545)</font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$     (601,924)</font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$   (439,506)</font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:43.089%;box-sizing:content-box;"></td>
     <td style="width:1.96%;box-sizing:content-box;"></td>
     <td style="width:12.402%;box-sizing:content-box;"></td>
     <td style="width:2.801%;box-sizing:content-box;"></td>
     <td style="width:12.362%;box-sizing:content-box;"></td>
     <td style="width:1.96%;box-sizing:content-box;"></td>
     <td style="width:11.662%;box-sizing:content-box;"></td>
     <td style="width:2.1%;box-sizing:content-box;"></td>
     <td style="width:11.662%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share &#x2014; basic and diluted</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$           (2.55)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$           (1.36)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$           (5.04)</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$         (4.00)</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares used in computing net loss per share &#x2014; basic and diluted</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;119,982</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;117,685</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;119,317</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;109,932</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img114956760_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114956760_0.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "7 5H# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5-+U*REGL]0T[4+.>&[LKVTFFMKNVFBG@EDBD1SHU_/A_P $D/V_=).DZ/\
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>XTF1HQ,WA\<_3R^C)P;EE;&8/CQ\9YDJ,JN#R+A#*\QS'&8R2?*H2S#$X?
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MSQ#JSV]SK^NW$9F%FNH7=M;6D*V>F0S26VEZ=:6UM96:27-SY,FI:CJM_?\
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MT_%3_P '?A'_ .8>OORBOQ'_ (D_^C-_T9K@[_PFQ?\ \U^7Y]V>=_8.3_\
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M-#=6=Y:S2V]S;RQS0R/&ZL4XRCI)-?UT>S^0XR4E>+N?G]^WO^WO_P ,0?\
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MN^AMM3T?5;2]TK5+2SU&SNK6%RA*/Q*W]>0HSC+X6GY=?N>I\/\ [>_[>_\
MPQ!_PJC_ (M1_P +._X6=_PG7_,]?\(7_8?_  A7_"'?]2=XL_M+^TO^$L_Z
MA_V/^S_^7K[5_HWT1^RC\>_^&GO@#X"^.7_"*?\ "$?\)Q_PE/\ Q2_]N_\
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M>SVM[XLU_P /6VMQZ%X@M/#DNLZMH]WIJ9I-NR3;\BVTE=NR75GUW17X1_\
M#]KX3?\ "?\ ]G?\*'^(G_"K?^AQ_P"$D\-?\)__ ,@7S_\ DFOE_P#"._\
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M_P!HG]K?5_ VL_#;_A)_A;X_\^ZT?POX.M-*6]^ &@:*JPQ>+-4\67L>B_\
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M5[:Q@UC1I;_]>?#7Q>_9V_:CMOB_\)?!WC?PU\6M)T70+#PO\4[/PO>ZC?\
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MWN;>>/3?$>C^)/#^B>D?'SX!_#/]I7X9ZW\*OBKHG]K>'=6VW5E>VK16VO\
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M\)O_ ,(/_P )3_Q2_P#PJC_A&O[4_P"$E\%^(_"'_(;_ .%E:_\ 8OL7]O\
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M+IK*PLK4PVL)152G*=KO1=%HO7^O\R8PC#5+5]6[Z'IU%%%06%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cytk-20251105.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-11-05T15:53:51.9884+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://cytokinetics.com/20251105" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:cytk="http://cytokinetics.com/20251105" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cytk-20251105.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  05,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cytokinetics, Incorporated<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001061983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3291317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">350 Oyster Point Boulevard<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">624-3000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CYTK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cytk-20251105.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="cytk-20251105.htm">cytk-20251105.htm</File>
    <File>cytk-20251105.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cytk-20251105.htm": {
   "nsprefix": "cytk",
   "nsuri": "http://cytokinetics.com/20251105",
   "dts": {
    "inline": {
     "local": [
      "cytk-20251105.htm"
     ]
    },
    "schema": {
     "local": [
      "cytk-20251105.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_d6445b24-9934-47c3-a4a1-2960f83d19e7",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cytk-20251105.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d6445b24-9934-47c3-a4a1-2960f83d19e7",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cytk-20251105.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cytokinetics.com/20251105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-25-266842-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-266842-xbrl.zip
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M!&M!WTDBXUB.R:<H80F/6$SZ3:]; "9OD;TX)L=8+2?',I?9F12MJM%! ?@
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MBOHF)>7OD-]_/?ZZ]MR>__;YY5!IO6?Q!66]]CX?[)W\=KS??T01?1,KJ\3
MD[?15M&U/TO@L,H\6RQTOS4K+"=*L+TY*S&4-BD.*J,Z!S3 ![2S"Q0/X&B$
M:#IC0TJFUP70?B[1OU#- 7\-T@P0(%HO(NG8N4]:KW6?2O>I,Q^Z%YQLM%XJ
M7R-MC;07CC2K=;=;1ZOR2U*TBV8*'7[I'>R?]+K]+=([Z!X>'QT>[YWL?WR4
M>T_60O2UD/8::6NDK9'V.A+;'T>9+2WDL]@MI>#N=%X -:\V%F^-"JX1>C^$
M_CI^PO-#5VU'U&N8P';>)O],!PDY;)%/K,QDSLNW*?]?B!Y>(VV-M#>)M)9[
MM^,]EAK57PB7-^2HVC']OT=;Y*,<E<68?):)S%3269GD,B8_L^%H&Z/WF2Q8
M-EZ!8U%7;37^M:\W[K2#5(P__+33'A3#^,-_ 5!+ P04    "  1@&5;4><4
M%V@(  !/70  $0   &-Y=&LM,C R-3$Q,#4N>'-D[5Q;;]LV&'W?K^#4EQ:K
M+,FIM\:H4WA),QA+DR!.L6+#4,@2;1.128^2$OO?CY1$W4S)CAU)=N ^-([T
M\? <\2)^)Z0_?5[,'/ (J8L([BE&2U< Q!:Q$9[TE&]#M3\\'PR4SV<_??I9
M5<'%Y> :7,,GT+<\] @OD&LYQ/4I!&^'7]^![[_?78&A-84S$UP0RY]![ $5
M3#UOWM6TIZ>GECU&V"6.[['JW)9%9AI0U0C\G$*37P<7I@=!MZVW.ZIAJ'KG
MWNAT.R?=CM$Z_?CQPR^ZWM7U5#$R7U(TF7K@K?4.\%*L;HRAX\ EN$38Q!8R
M'3 4M;X' VRU0-]QP!TOYH([Z$+Z".U6"+IP[:X;BO!,.H'>M3F#[MRT8$^)
MI%A+CSP@##UDA2IXM8:A=Q1@>AY%(]^#EX3.+N#8]!VOI_CX/]]TT!A!FSU@
M!_(GDPE(W68M@MTNQ/ZL'5>X&%&G1>B$5Z1K<.%![**1 U4>!FGPW%RUS9LO
M+,X8/FQ"-XQFDN-@WDQ/)U%ENJ%]_WH5-JD(=A!^R$2GR.DG&K\],ETHPGU7
MG9CF/"XQ-MU1$!W=",B(8!NBK&876JT)>=38C4P@OVE[LN>C=[3P9CH4E1!F
M/=)CG20FO%@1&#T.X_3T5 ON*F<_ 1!T%#2;$^J!L+]<$2MHB9+*^&^JJ%'E
MEU2CK9X8+0:F +S2TTKH:KN1$.VT%8FXD;<E(1J)U]XIJE?:JAO5Z(K2TMZF
M0<=SQ1657REB(.^LSZ.0[\+\0VFE\HZ?5&IB3+R@)GY)7)S/$1Z3\ J[QENH
M2XD#[Y=S"/B';W>#]3."YID+@LELJ?$BFIC%Q<\^MK]@#WG+ :N+S@(2"D!L
M]KACX3\V"A<4!4D;LI<""N08.O_'7AFIMT?\D8&!$ VDX#YI>9 <O.]"^P:?
M!9_GE$WU.'QV5^Q"5#@**2EHF8[E.\\OE] J+!9=%$V5;4 QSH)'[$033[Z%
M[^"XX@8.)KWNE,)Q3^%O%E6@\2[\9O.FCX \IK.GN&SP.-$,DM%LCJ##'U<4
MS7F63$6!C&!2%NC(XP5BF&RMP;O39N_9I-JX8F)E0AT^G@G-RM]\:+]AO_PX
M)VQQU1^Y'C4M3R %U'K*ZGVM'E)]UD!VL 1QS(F$5/9^3:3.65_ILR7@.;&A
M[$&E;]=$2?3E6T@18=W9YBM3"3=Y7,TD^>11PBVX71.E<.#W;9M-MV[T@XU$
M:$CX%<<V09;WLAMZ3Y[P.JJIR":(WA*V"G3^1O."X5(2W 3=(7OGPAMZ2\DC
M"I?:I83SX;52/F>CA9K.@+TE%G_"92'7?%RM)+^PK&_"DO0_*'GRIN=D-C=Q
M,55Y=*V$+Y$#K_W9"-)"EJF06JD-L$4H6\<':Y2@ZYT3G[7MLG1LE9>J5< =
MG""^@L"!55'(.!=6*\5[<S&PV8!!8Q0F26OZ0E%\3:1Y*N?<3@DN[K,K(351
MNZ6LH\W8*]T*7*2!Z_J0WO,U+;T9CZ54UQ9IAOJS2#= =P@MG[*^:+1']SRG
MD)!<":F9VI>%-37Q!!:,>VE8712)@RR6^N+)5S8W4F0Z,H*K0371NZ<F-[F'
MR]F(R)AE[]=$ZB_66"P]Y?W>Q]'$YTK(R>-D)'D9[FNR3]S1AUC]-LPFQ&R]
M17PJ79-EDM,?SBA^3ANEY!Q'.0LPP#\"Y=_([@CNOC3?3-ZZ)=\8 W"0*MFF
M,]IM'RXWPS@&X"!5DI6FN%NRCAV]$ PPM.!O/G7PYVGPKK0Y1I5<"U/B+8E'
MIFF$]%Y\ !P3W.#ZM"0Y\PLI"?H_H8!#UJ8BDTV_D) 0$S#0RD=R6:+]0FH"
M5-XN K=Z/;ED?#<A$1@(T "#JYZ_-$/?386 !"$FB$"KUY+D\;L)X#@@!*J>
M=&DZOYN.#'1J=$05U#3BL]G_;HH2+,#!JB=?8 ?LIH*!@BQJ#;TM;QML*2&
M 0%.#:37&0A;BF"PJI7"!2$P")%! %VCK H$U:4D[T-LR3\H"\@8&.VWHW=
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M\^<( 7,G%:#]KQH/(O%'*B,]3)6]5Y=2F;,L6W[N2(_S?2B?/@Z++KK4S]2
M0A@6^MU@KD6LS*^VU&+%72A GG 8<C02D7+YX>(\/A2>&CM"X$SFT(#=CZ17
M*C>[28@)6#/2]X(W .9,18"S*K.DKJW1GEI(#;F77Z)$B MDH_2@'AQJ.O&7
M1/.]%)25<DCX[C=R4\;1TF%DLDU),)5-<[CX!0RI/P[YM= "LL)'B8AZW+OE
MT]C(Q!E2BT@M>E'L43H$88$B!"R8$*21EC/(Y8[YE-GU&OL(*(76RF\@@[3
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M+U>%ERLK]1-8I.<%B]1H()H8Y)873LV#W1:MCA)Y4TR"++OG35GI.<$B%IY
M'YSPH\#SE$:6Y8G^@X<<;U7'F$VVH.@6$T$QXVR,U7#!!%(A17GN199TEJ=D
M9./LB;O\FEZ-K[*C?JL_DAY*MAK9:J]EJQWUSP8?/VHD+L;7$LMY)9:C:%H
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M8-7*G:M58[O:G;'[!6] K: *Y@/%? (J&G"Y )4X'*9)FMFN<^T\0@5LD6+
MV-Z%*IAXO,\&F6E$C)T8.S'VYU&9IJ6YE^$IK!VL^7K.PI?<.*CGMZIVT=T
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MI:MP @]$=81,$RPU/.>:Q>D/BSRTR 87[Y;R PJ#$)>%D]^.\0!3SP55W!>
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MF$Y[2TY[3Z7*!&G,?3?>?X-C72$IW^+H[F/3!H[RX<-[KIJY2A!O 27D1T3
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M-2YH=&U02P$"% ,4    "  1@&5;4><4%V@(  !/70  $0
M@ 'K$@  8WET:RTR,#(U,3$P-2YX<V102P$"% ,4    "  1@&5;D)NT_4HX
M  #9/00 #P              @ &"&P  8WET:RUE>#DY7S$N:'1M4$L%!@
0   #  , NP   /E3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>cytk-20251105_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cytk-20251105.xsd" xlink:type="simple"/>
    <context id="C_d6445b24-9934-47c3-a4a1-2960f83d19e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier>
        </entity>
        <period>
            <startDate>2025-11-05</startDate>
            <endDate>2025-11-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_70228bea-6f57-4a6c-acc1-ada482a04bae">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_f28bb2b3-0af5-4451-838f-269fcb5935fa">0001061983</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_512083fb-19fc-4335-8dff-d3e6fb2f3ba1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_15d5141c-9406-45b1-8f86-dcd282e12827">2025-11-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_f1336f4d-3200-4307-831f-8faa3f0926cd">Cytokinetics, Incorporated</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_be221fad-c564-4e96-ad93-ad32a2cc1da5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_70d8bc4a-c476-4ae0-93cb-83c921b735d4">000-50633</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_96b9266c-7ef5-4993-a0b9-985cf4760737">94-3291317</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_7ded9270-6dd4-49f5-9b5c-352d077a7fa7">350 Oyster Point Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_aa31b3cb-622c-4d0f-8047-c63a39766d8f">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_746461e0-9411-438f-a3c7-c40463f6602a">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_508c1ef9-8fee-4dbd-8ee9-72b10d9ba603">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_afaf7e71-27c6-48b3-a507-e67296b62ecc">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_1b7a7d51-7c6e-4e71-a9ae-e948813e7fb1">624-3000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_d19c1c6a-98d9-4c29-9959-7c5e71761d91">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_f20638e8-746b-4942-97ca-c95f03095864">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_ccd98a4d-3b69-48f3-afd2-04684debb5a5">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_0967a0b4-0f43-4a03-9e0d-37da1e486e9b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_19030593-36cb-4dfc-adcf-533fcda9e460">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_0cc71bd1-8a2f-4cf3-81fc-83ca73446609">CYTK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_ff1cc826-8970-4197-a9fd-6b8705b96e80">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_d6445b24-9934-47c3-a4a1-2960f83d19e7"
      id="F_be6194d2-0ecc-4532-8f65-612b8cf82293">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
